--- title: "Cellectar Bioscience | 8-K: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286407251.md" datetime: "2026-05-14T11:22:12.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286407251.md) - [en](https://longbridge.com/en/news/286407251.md) - [zh-HK](https://longbridge.com/zh-HK/news/286407251.md) --- # Cellectar Bioscience | 8-K: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -1.33, beating the estimate of USD -1.885. EBIT: As of FY2026 Q1, the actual value is USD -5.857 M. ### Financial Highlights (First Quarter 2026) #### Cash and Cash Equivalents Cellectar Biosciences, Inc. (Cellectar 生物科学) reported cash and cash equivalents of $8.3 million as of March 31, 2026, which is a decrease from $13.2 million as of December 31, 2025 . This balance does not include net proceeds of approximately $31 million from a May 2026 offering . The company believes its cash balance, combined with funds from the May 2026 financing, is sufficient to fund budgeted operations into the second quarter of 2027, including the initiation costs for the iopofosine I 131 confirmatory study in Waldenström Macroglobulinemia (WM) . #### Research and Development Expenses Research and Development (R&D) expenses for the three months ended March 31, 2026, were approximately $3.0 million, a decrease from approximately $3.4 million for the same period in 2025 . This reduction was primarily due to decreased clinical and preclinical study costs, partially offset by increased spending for product manufacturing processes . #### General and Administrative Expenses General and Administrative (G&A) expenses for the three months ended March 31, 2026, were approximately $2.8 million, down from approximately $3.0 million for the same period in 2025 . This decrease was mainly a result of reduced personnel costs . #### Total Operating Expenses Total operating expenses for the three months ended March 31, 2026, were $5,793,942, compared to $6,400,991 for the three months ended March 31, 2025 . #### Loss From Operations Loss from operations for the three months ended March 31, 2026, was -$5,793,942, an improvement from -$6,400,991 for the same period in 2025 . #### Other Income (Expense) - **Gain (loss) on valuation of warrants**: Cellectar Biosciences, Inc. reported a gain of $77,000 for the three months ended March 31, 2026, compared to a loss of -$340,000 for the same period in 2025 . - **Interest income**: Interest income for the three months ended March 31, 2026, was $62,996, down from $136,962 for the same period in 2025 . - **Total other income (expense)**: Total other income (expense) for the three months ended March 31, 2026, was $139,996, compared to -$203,038 for the same period in 2025 . #### Net Loss The net loss attributable to common stockholders for the three months ended March 31, 2026, was -$5.7 million, or -$1.33 per share, which is an improvement from a net loss of -$6.6 million, or -$4.30 per share, in the three months ended March 31, 2025 . ### Operational Metrics #### Financing Activities In May 2026, Cellectar Biosciences, Inc. completed an oversubscribed financing of up to $140 million, which included approximately $35 million upfront and up to $105 million in milestone-based securities . This financing was led by Nantahala Capital, with participation from Balyasny Asset Management, Caligan Partners, Janus Henderson Investors, SilverArc Capital Management, and other dedicated healthcare funds . #### Clinical Trial Progress - Iopofosine I 131 Cellectar Biosciences, Inc. reported positive 12-month follow-up data from its Phase 2b CLOVER WaM study evaluating iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) . The study demonstrated a 61.8% major response rate (MRR) and a median duration of response (DoR) of 17.8 months in the protocol study population (n=55) . Additional data included an overall response rate (ORR) of 83.6%, median progression-free survival (PFS) of 13.5 months, a very good partial response/complete response rate (VGPR/CR) of 14.5%, and a disease control rate (DCR) of 98.2% . Data from the CLOVER WaM study is also selected for presentation at the American Society of Clinical Oncology Annual Meeting (ASCO) from May 29 - June 2, 2026 . #### Clinical Trial Progress - CLR 125 The company announced the enrollment of the first patient in the Phase 1b trial evaluating CLR 125 in refractory triple negative breast cancer (TNBC) . ### Outlook / Guidance Cellectar Biosciences, Inc. is advancing plans to initiate a Phase 3 confirmatory trial of iopofosine I 131 for WM and file for accelerated approval with the U.S. FDA, with full patient enrollment projected within 18-24 months of the first patient admitted to the study . The company is also working with the European Medicines Agency (EMA) to file for a Conditional Marketing Approval (CMA) for iopofosine I 131 for post-BTKi refractory WM patients . For CLR 125, the company anticipates activating additional study sites throughout the second quarter of 2026 and expects to provide dosimetry, safety, and efficacy updates in the second quarter and throughout the balance of 2026 . ### Related Stocks - [CLRB.US](https://longbridge.com/en/quote/CLRB.US.md) ## Related News & Research - [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md) - [Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates | CLRB Stock News](https://longbridge.com/en/news/286406208.md) - [Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026 | GOSS Stock News](https://longbridge.com/en/news/286553329.md) - [Compugen Reports First Quarter 2026 Results | CGEN Stock News](https://longbridge.com/en/news/286758883.md) - [Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update | CTOR Stock News](https://longbridge.com/en/news/286611095.md)